Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29914245 | 1.00 | ADORA1 (0.68) | ADORA1ADORA2AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL3399237 | 0.81 | ADORA2A (0.68) | ADORA1ADORA2AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL3398538 | 0.81 | ADORA2A (1.00) | ADORA1ADORA2AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL3530116 | 0.81 | ADORA2A (0.68) | ADORA1ADORA2AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL2322824 | 0.81 | ADORA2A (0.68) | ADORA1ADORA2AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL2322815 | 0.81 | ADORA2A (0.68) | ADORA1ADORA2AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL2320438 | 0.81 | ADORA2A (0.53) | ADORA1ADORA2AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL2323331 | 0.80 | ADORA2A (0.62) | ADORA1ADORA2AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL2325695 | 0.80 | ADORA2A (0.67) | ADORA1ADORA2AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL31009002 | 0.80 | ADORA2A (0.67) | ADORA1ADORA2AALDH1A1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | NXERA PHARMA UK LIMITED (GB) | 2024-08-06 | — | — | US | disclosed |
| CN-113166119-B | Substituted aryl compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230021177-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-20210395226-A1 | SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-12-23 | — | — | US | disclosed |
| CN-113166119-A | Substituted aryl compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-10988455-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-27 | — | — | US | disclosed |
| US-20190047978-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2019-02-14 | — | — | US | disclosed |
| US-10112923-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-10-30 | — | — | US | disclosed |
| US-20170291888-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20160175314-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-06-23 | — | — | US | disclosed |
| EP-2531492-B1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LTD (GB) | 2016-04-13 | — | — | EP | disclosed |
| US-9249130-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-20150005276-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-8809525-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-08-19 | — | — | US | disclosed |
| US-20130029963-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| EP-2531492-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | Heptares Therapeutics Limited (GB) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011095625-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2011-08-11 | — | — | WO | disclosed |
| WO-2010046780-A2 | ANTI VIRAL COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010046780-A2 | ANTI VIRAL COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2010-04-29 | — | — | WO | disclosed |
| CN-101641093-A | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORP US | 2010-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005276-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885ALDH1A1 784/4885 |
| US-20190047978-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885ALDH1A1 784/4885 |
| US-10988455-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2B, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885ALDH1A1 784/4885 |
| US-20160175314-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885ALDH1A1 794/4885 |
| US-20230021177-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885ALDH1A1 788/4885 |
| US-10112923-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2B, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885ALDH1A1 763/4885 |
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2A, ADORA2B, ADORA1 | ADORA1 3/4885ADORA2A 1/4885ALDH1A1 251/4885 |
| US-20170291888-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | PTGER1, LTB4R2, LTB4R | ADORA1 19/4885ADORA2A 29/4885ALDH1A1 1211/4885 |
| US-20210395226-A1 | SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885ADORA2A 1/4885ALDH1A1 612/4885 |
| US-20130029963-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885ALDH1A1 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.